OncoCyte Corp (OCX)
2.71
+0.04
(+1.50%)
USD |
NASDAQ |
Nov 22, 16:00
OncoCyte Debt to Equity Ratio: 0.00 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.0065 |
| Date | Value |
|---|---|
| March 31, 2022 | 0.0166 |
| December 31, 2021 | 0.0201 |
| September 30, 2021 | 0.0169 |
| June 30, 2021 | 0.0199 |
| March 31, 2021 | 0.0332 |
| December 31, 2020 | 0.1164 |
| September 30, 2020 | 0.1191 |
| June 30, 2020 | 0.1037 |
| March 31, 2020 | 0.0837 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Sep 2022
0.1191
Maximum
Sep 2020
0.0282
Average
0.0065
Median
Jun 2022
Debt to Equity Ratio Benchmarks
| Fonar Corp | 0.0005 |
| XWELL Inc | 0.00 |
| ProPhase Labs Inc | 0.4506 |
| Applied DNA Sciences Inc | 0.00 |
| Veracyte Inc | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 70.22M |
| Total Liabilities (Quarterly) | 60.50M |
| Shareholders Equity (Quarterly) | 9.711M |
| Current Ratio | 0.5273 |